On March 9, 2023 Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop antibody therapeutics to improve patient care, reported that Matthew Robinson, Ph.D., Chief Technology Officer, will present at the 13th Annual World ADC London conference, taking place from March 13-16, 2023 (Press release, Immunome, MAR 9, 2023, View Source [SID1234628485]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
World ADC London is Europe’s longest standing and definitive antibody-drug conjugate (ADC) event dedicated to maximizing the therapeutic window of ADCs. Dr. Robinson will give a platform talk on Wednesday, March 15 discussing how Immunome’s Discovery Engine can highlight novel target classes which have relevance for multiple therapeutic modalities, including ADCs. Full presentation details are included below.
"Human memory B cells are able to record the targets that are classified as important attack points for antibodies across the course of tumor development. With our proprietary Discovery Engine, we can harness this information through an unbiased interrogation of the patient memory B cell response – at an industrial scale – to identify novel targets and antibodies that bind them," Dr. Robinson commented. "Our research has revealed novel target classes, such as proteins abnormally expressed on the surface of cancer cells, which we believe are uniquely tumor selective and potentially suitable for development as ADCs. With the help of our newly established Antibody-Drug Conjugate and T Cell Redirection Advisory Board, I look forward to further exploring how we can apply this approach to advance new ADC therapeutics and improve cancer treatment."
Presentation Details:
Title: Harnessing the Power of the Human Memory B Cell
Presenter: Matthew Robinson, Ph.D., Chief Technology Officer
Date: March 15, 2023, 12:00 p.m. GMT / 7:00 a.m. ET
A copy of the presentation will be available on the Events & Presentations section of Immunome’s website following the conference.